Short-term efficacy of combination of 125I seed brachytherapy and cetuximab in postoperation recurrent rectum cancer
10.3760/cma.j.issn.0254-1432.2019.05.013
- VernacularTitle:放射性125I粒子植入联合西妥昔单克隆抗体治疗直肠癌术后复发的近期疗效
- Author:
Jian WANG
1
;
Xikun ZHANG
;
Bin WANG
;
Shancheng LI
;
Lin SUN
;
Wen SUN
;
Liang HAO
;
Hongxin NIU
Author Information
1. 山东省医学科学院附属医院微创外科
- Keywords:
Recurrent rectum cancer;
125I seeds;
Cetuximab monoclonal antibody
- From:
Chinese Journal of Digestion
2019;39(5):337-341
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short-term efficacy of combination of 125 I seed brachytherapy and cetuximab in postoperation recurrent rectum cancer.Methods From July 2014 to June 2018,at Affiliated Hospital of Shandong Academy of Medical Sciences,57 patients with postoperation recurrent rectal cancer were recruited.According to therapy the patients were divided into two groups:the radiotherapy group (30 cases) treated with radioactive 125I seeds alone and the combination treatment group (27 cases) treated with combination of radioactive 125I seeds and cetuximab.The tumor size,pain relief and adverse reactions were observed in both groups.Chi-square test were performed for statistical analysis.Results After treatment for six months,the total efficacy rate and local control rate of combination treatment group were 54.2％ (13/24) and 87.5％ (21/24),respectively;and which were higher than those of radiotherapy group (17.9％,5/28 and 39.3％,11/28),and the differences were statistically significant (x2 =15.01 and 2.55,both P ＜ 0.05).At one month after treatment,the pain relief rate of radiotherapy group and combination treatment group was 70.0％ (21/30) and 85.2％ (23/27),respectively,and there was no statistically significant difference between the two groups (P ＞ 0.05).After treatment for six months,the rates of adverse reactions of radiotherapy group and combination treatment group were 46.7 ％ (14/30) and 63.0％ (17/27),respectively,there was no statistically significant difference between the two groups (P ＞ 0.05).The symptoms of patients with radiation injury significantly improved after symptomatic treatment.Conclusion The short-term efficacy of combination of 125 I seed brachytherapy and cetuximab is better than that of 125 I seed brachytherapy alone in patients with postoperation recurrent rectum cancer.
